Companies › NingBo Junyan Hongshi Biosciences
1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout Jan 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| JS107 anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 3 | Gastric Adenocarcinoma | Jan 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07584135 | JS107 | Phase 3 | Gastric Adenocarcinoma | Oncology | Jan 2029 |
I-Mab Biopharma US Suzhou Immunofoco Biotechnology LaNova Medicines Zhejiang FutureGen Biopharmaceutical (Beijing) SynOx Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.